Methylation & Proteomics-Based Detection of Bladder Cancer
- Cairns, Paul — Fox Chase Cancer Center
- Bochner, Bernard — Memorial Sloan-Kettering Cancer Center
- Feng, Ziding — Fred Hutchinson Cancer Research Center
- Helber, Sarah — AIBioTech
- Steinberg, Gary D. — University of Chicago Urology Center
- Wei, John — University of Michigan
- Wagner, Andrew — Beth Israel Deaconess Medical Center
- Schoenberg, Mark P. — Johns Hopkins University
- Kibel, Adam — Brigham and Women's Hospital
- Sidransky, David — Johns Hopkins University School of Medicine
- Srivastava, Sudhir — National Cancer Institute
- Shore, Neal — CURC/Carolina Urologic Research Center
- Thompson, Ian M. — University of Texas Health Science Center at San Antonio
- Czerniak, Bogdan — The University of Texas MD Anderson Cancer Center
To determine sensitivity and specificity of quantitative real-time methylation specific PCR (qMSP) of urine sediment DNA, using a panel of several methylated gene markers, in detecting bladder cancer in participants pathologically confirmed to have this disease. Secondary objective: to test the sensitivity and specificity of an Aurora A FISH probe for the detection of clinically evident bladder cancer.
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.